c-CCyRS according to the dose intensity received by the patients during the first 3 months of therapy and reason for dose adjustment. The 39 patients (gray line) who had their therapy with the first-choice 2G-TKI temporarily discontinued or dose reduced because of hematologic toxicity during the first 3 months of treatment had a significantly worse 4-year probability of c-CCyRS than the 54 patients who did not require dose modification, represented by the black line, (26.4% vs 64.5%, P = .001). Conversely, the 23 patients who had their dose of 2G-TKI modified because of nonhematologic toxicity (broken black line) had a 4-year c-CCyRS comparable to that of patients with good tolerance to therapy (55.5% vs 64.5%, P = .64), which was significantly higher than that of patients with hematological intolerance (P = .02).